Regulating drug prices: Where do we go from here?

Fiscal Studies

Volumn 19, Issue 3, 1998, Pages 321-342

  Bloom, Nicholas ^a   Van Reenen, John ^a,b,c  

^a INSTITUTE FOR FISCAL STUDIES   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001131406     PISSN: 01435671     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1475-5890.1998.tb00290.x     Document Type: Article

References (31)

1. Adams, J. and Jaffe, A. (1996), 'Bounding the effects of R&D: an investigation using matched establishment-firm data', Rand Journal of Economics, vol. 27, pp. 700-21.
2. Armstrong, M., Cowan, S. and Vickers, J. (1994), Regulatory Reform, Cambridge, Mass.: MIT Press.
3. Attridge, J. (1995), International Comparisons of Pharmaceutical Prices in Europe, British Pharma Group Policy Pamphlet, Uxbridge: British Pharma Group.
4. Audit Commission (1994), A Prescription for Improvement, London: HMSO.
5. _ (1995), What the Doctor Ordered, London: HMSO.
6. Averch, H. and Johnson, L. (1962), 'Behaviour of firms under regulatory constraint', American Economic Review, vol. 52, pp. 1052-69.
7. Baines, D., Whynes, D. and Tolley, K. (1997), 'General practitioner fundholding and prescribing expenditure control', Pharmacoeconomics, vol. 11, pp. 350-8.
8. Bloom, N. and van Reenen, J. ( 1997). 'Why has the UK pharmaceutical industry been successful?', mimeo, Institute tor Fiscal Studies.
9. Bloor, K. and Maynard, A. (1997), 'Regulating the pharmaceutical industry', British Medical Journal, vol. 315, pp. 200-1.
10. Burstall, M. (1997), 'How do they do it elsewhere in Europe?', in D. Green (ed.). Should Pharmaceutical Price Be Regulated?, London: Institute of Economic Affairs.
11. Caves, M. and Towse, A. (1997), 'Regulating prices paid by the NHS for medicines supplied by the UK-based pharmaceutical industry', Office of Health Economics, Briefing no. 34.
12. Danzon, P. (1997), Trade and Price Differentials for Pharmaceuticals: Policy Options, London: Office of Health Economics.
13. Department of Health (1993), Pharmaceutical Price Regulation Scheme, October, London: Department of Health.
14. _ (1994), Government Response to the Second Report from the Health Committee Session 1993-94, Cm. 2683, London: HMSO.
15. _ (1996), Pharmaceutical Price Regulation Scheme Report to Parliament, London: Department of Health.
16. _ (1997), Pharmaceutical Price Regulation Scheme Second Report to Parliament, London: Department of Health.
17. Dilnot, A. (1996), 'The assessment: the future of the welfare state', Oxford Review of Economic Policy, vol. 11, no. 3, pp. 1-10.
18. Drummond, M., Jonsson, B. and Rutten, F. (1997), 'The role of economic evaluation in the pricing and reimbursement of medicines', Health Policy, vol. 40, pp. 199-215.
19. Grabowski, G. and Vernon, J. (1994), 'Returns to R. & D. on new drug introductions in the 1980s', Journal of Health Economics, vol. 13, pp. 389-405.
20. Griliches, Z. and Cockburn, I. (1995), 'Generics and the producer price index for pharmaceuticals', in R. Helms (ed.), Competitive Strategies in the Pharmaceutical Industry, Washington DC: AEI Press.
21. Kavanos, P. (1998), 'Single European currency and monetary union: macroeconomic implications for pharmaceutical spending', Pharmacoeconomics, vol. 13, pp. 9-20.
22. Laffont, J. and Tirole, J. (1994), A Theory of Incentives in Procurement and Regulation, Cambridge, Mass.: MIT Press.
23. Mayer, C. and Vickers, J. (1996), 'Profit-sharing regulation: an economic appraisal', Fiscal Studies, vol. 17, no. 1, pp. 1-18.
24. Mossialos, E. (1997), An Evaluation of the PPRS: Is There a Need for Reform?, in D. Green (ed.), Should Pharmaceutical Price Be Regulated?, London: Institute of Economic Affairs.
25. OECD (1997), Structural Analysis Industrial (STAN) Database, Paris: Organisation for Economic Co-operation and Development.
26. Office of Health Economics (1997), Compendium of Health Statistics 1997, London: Office of Health Economics.
27. Reekie, W. D. (1997), The PPRS: Regulations without a Cause?, in D. Green (ed.), Should Pharmaceutical Price Be Regulated?, London: Institute of Economic Affairs.
28. Stiglitz, G. (1971), 'The theory of economic regulation', Bell Journal of Economics, vol. 6, pp. 3-21.
29. Sutton, J. (1997), 'Not by technology alone', mimeo, London School of Economics.
30. Thomas, L. G. (1994). 'Implicit industrial policy: the triumph of Britain and the failure of France in global pharmaceuticals', Industrial and Corporate Change, vol. 3, pp. 451-89.
31. Trade and Industry Committee (1996-97), First Report: Energy Regulation, HC50-1, London: HMSO.